File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hematological features and treatment outcome in acute myeloid leukemia with t(8;21)

TitleHematological features and treatment outcome in acute myeloid leukemia with t(8;21)
Authors
KeywordsAcute myeloid leukemia
Cytogenetics
Prognosis
t(8
21)
Treatment outcome
Issue Date1997
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1997, v. 15 n. 2, p. 93-103 How to Cite?
AbstractWe analyzed the hematological features and treatment outcome in 18 patients with t(8;21) acute myeloid leukemia (AML) diagnosed in Queen Mary Hospital, Hong Kong. They comprised 15 cases of M2, two cases of M4 and one case of M1 according to FAB criteria. Auer rods (17 cases) and dysgranulopoietic features (15 cases) were very frequently observed. Two cases showed marrow eosinophilia while blast cells in one patient demonstrated erythrophagocytic activity. Chromosome changes in addition to t(8;21) were seen in 14 patients, the most common of which was loss of a sex chromosome (10 cases). Of the 14 patients treated with intensive chemotherapy, 13 (93 per cent) entered complete remission with a median event-free survival (EFS) and overall survival (OS) of 11 and 24 months respectively. The probability of EFS and OS at 3 years were 33 ± 14.3 per cent and 55.1 ± 15.6 per cent respectively with a median duration of follow- up of 22 months. When compared with AML having no t(8;21) treated similarly in the same period, we could not demonstrate a better clinical outcome for t(8;21) AML.
Persistent Identifierhttp://hdl.handle.net/10722/148079
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMa, SKen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLam, CKen_HK
dc.contributor.authorLiang, RHSen_HK
dc.contributor.authorChan, LCen_HK
dc.date.accessioned2012-05-29T06:10:44Z-
dc.date.available2012-05-29T06:10:44Z-
dc.date.issued1997en_HK
dc.identifier.citationHematological Oncology, 1997, v. 15 n. 2, p. 93-103en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148079-
dc.description.abstractWe analyzed the hematological features and treatment outcome in 18 patients with t(8;21) acute myeloid leukemia (AML) diagnosed in Queen Mary Hospital, Hong Kong. They comprised 15 cases of M2, two cases of M4 and one case of M1 according to FAB criteria. Auer rods (17 cases) and dysgranulopoietic features (15 cases) were very frequently observed. Two cases showed marrow eosinophilia while blast cells in one patient demonstrated erythrophagocytic activity. Chromosome changes in addition to t(8;21) were seen in 14 patients, the most common of which was loss of a sex chromosome (10 cases). Of the 14 patients treated with intensive chemotherapy, 13 (93 per cent) entered complete remission with a median event-free survival (EFS) and overall survival (OS) of 11 and 24 months respectively. The probability of EFS and OS at 3 years were 33 ± 14.3 per cent and 55.1 ± 15.6 per cent respectively with a median duration of follow- up of 22 months. When compared with AML having no t(8;21) treated similarly in the same period, we could not demonstrate a better clinical outcome for t(8;21) AML.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.-
dc.subjectAcute myeloid leukemiaen_HK
dc.subjectCytogeneticsen_HK
dc.subjectPrognosisen_HK
dc.subjectt(8en_HK
dc.subject21)en_HK
dc.subjectTreatment outcomeen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshChilden_US
dc.subject.meshChromosomes, Human, Pair 21en_US
dc.subject.meshChromosomes, Human, Pair 8en_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Myeloid - Genetics - Physiopathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOutcome Assessment (Health Care)en_US
dc.subject.meshTranslocation, Geneticen_US
dc.titleHematological features and treatment outcome in acute myeloid leukemia with t(8;21)en_HK
dc.typeArticleen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, RHS:rliang@hku.hken_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, RHS=rp00345en_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1099-1069(199705)15:2<93::AID-HON603>3.0.CO;2-Gen_HK
dc.identifier.pmid9375034-
dc.identifier.scopuseid_2-s2.0-0030831685en_HK
dc.identifier.hkuros28760-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030831685&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue2en_HK
dc.identifier.spage93en_HK
dc.identifier.epage103en_HK
dc.identifier.isiWOS:A1997YE59700005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMa, SK=9042504200en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLam, CK=7402990801en_HK
dc.identifier.scopusauthoridLiang, RHS=26643224900en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats